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Modulation of BACE1 activity by chemically modified aptamers 
Cécile Gasse,*[a] Marwa Zaarour,[a] Sam Noppen,[b] Mikhail Abramov,[c] Philippe Marlière,[d] Sandra 
Liekens,[b] Bart De Strooper,[e] Piet Herdewijn*[a, c]  
 
Abstract: A modified DNA aptamer was developed that binds 
BACE1, a therapeutic target involved in Alzheimer’s disease. This 
ssXNA not only tightly binds to BACE1 but also inhibits its protease 
activity in vitro in the same range as a previously described 
unmodified aptamer. We report the in vitro selection of functional 
oligonucleotides using two nucleobase modifications: 5-chlorouracil 
and 7-deazaadenine. The nucleoside analog 5-chloro-2’-
deoxyuridine has already been explored to replace thymidine in a 
chemically modified genome of a bacterium. Thus, 5-chlorouracil 
modification is a good candidate to support genetic transfer in vivo 
as well as functional activity. 
Introduction 
Halogenated uracil residues enjoyed a revival in interest over 
the last few years from a genetical and biochemical point of view. 
5-chlorouracil (5-ClU) was previously synthesized in the 1950’s 
but has not been extensively studied as much as other 
halogenated pyrimidine derivatives, possibly because potential 
therapeutic applications were not visible.[1]  
More recently, Marlière et al. brought the chlorouracil 
modification to the forefront of synthetic biology by challenging 
cells to replicate with this artificial nucleobase instead of the 
natural thymine.[2] For that purpose, they engineered an E. coli 
strain that required exogenous thymine for growth. 98.5% of its 
genome contained 5-chlorodeoxyuridine in place of genomic 
deoxythymidines. This seminal work was the first example in the 
construction of biological systems composed of xenonucleic 
acids (XNAs) through evolutionary pressure. The choice of 5-
ClU was in part based on the fact that 5-ClU or 5-CldU were well 
known for incorporation into DNA[3-7] and could form a 
biophysically stable base pair with adenine. Further 
investigations into the development of artificial genomes were 
carried out by using fully nucleobase-modified DNA with 5-
chloro-2’-deoxyuridine, 7-deaza-2’-deoxyadenosine, 5-fluoro-2’-
deoxycytidine, and 7-deaza-2’deoxyguanosine.[8] Originally, the 
7-deaza-2’-deoxyadenosine (or tubercidin) was characterized for 
antiviral, antitrypanosomal, and antifungal functions.[9,10] The 
choice of 5-chlorouracil and its base-pairing partner, 7-deaza-2’-
deoxyadenosine as a new base-pair couple relied on their 
chemical stability and their physicochemical properties.[11,12] The 
resulting XNAs were shown to be replicated in vitro by the Taq 
polymerase under polymerase chain reaction (PCR) conditions 
on very long templates (> 2000 nucleotides) and to serve in vivo 
as artificial genetic templates along with a 5-fluorocytosine: 7-
deazaguanine base pair. These findings went along with 
previous studies which demonstrated that alternative backbone 
modifications, such as triazole units, replacing the natural 
phosphodiester bond could also assume this function.[13,14] 
Moreover, the implementation of a modified information system 
able to sustainably replicate was firstly conducted by using a 
single base pair system in E. coli.[15]  
In the present work, we sought to explore the potential of such a 
redesigned base-pair system in the applied context of functional 
nucleic acids. In a long-term goal, production of modified nucleic 
acids with a dedicated function could be accomplished by using 
living systems tolerant to chemical modifications, as proven by 
the engineered E. coli growing on 5-ClU. Aptamers are single-
stranded synthetic oligonucleotides that can adopt well-defined 
three dimensional structures and thus bind specifically and 
selectively to a target molecule.[16] They can be generated by 
applying the SELEX procedure (Systematic Evolution of Ligand 
by Exponential enrichment) from libraries of randomized single-
stranded DNA or RNA molecules with a predetermined diversity. 
Recent developments have been oriented to increase the 
chemical diversity in the scaffold of aptamers which in turn will 
enhance their stability towards nuclease degradation and 
improve their binding affinity, especially towards hydrophobic or 
positively charged targets by using chemically-modified 
nucleotides during the selection protocol.[17-24] The same 
approach has been applied for catalytic nucleic acids.[25-28] We 
decided to use this chemistry to tackle the aspartyl protease 
beta-secretase 1 (BACE1), an important drug target in 
Alzheimer’s Disease (AD).[29] Cerebral accumulation of amyloid 
β peptide (Aβ) is thought to be central at an early stage in the 
pathogenesis of AD. This peptide is generated by a sequential 
cleavage of the amyloid precursor protein (APP) by β- and γ-
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secretases. BACE1 has been identified as the β-secretase 
involved in APP processing and is thus considered as an 
attractive drug target for potential AD treatment. The feasibility of 
the approach has been validated by the selection of RNA 
aptamers recruited to the cytoplasmic domain of BACE1[30] and 
more recently DNA aptamers against the ectodomain of BACE1 
containing its catalytic site.[31] In our current work, we describe 
the in vitro selection of aptamers against BACE1 using an 
alternative base pair system where the thymidine was 
substituted by a 5-CldU and adenosine by its 7-deaza analogue 
(Figure 1).[32,33] We clearly demonstrate that the incorporation of 
these nucleobase modifications into the random oligonucleotide 
library, significantly modified the outcome of the selection 
process against BACE1. Binding and modulatory activity of the 
newly chemically modified aptamers are also discussed. This 
selection experiment represents a step towards the crafting of 
modified genetic systems capable of modulating enzymes 
involved in AD and could be expanded to other 
neurodegenerative diseases. 
 
Figure 1. Chemical structure of the modified nucleotides used during SELEX 
processes. 
Results and Discussion 
Amplification with modified triphosphate precursors 
We chose the D1 DNA library comprising a 49 nucleotide-long 
random region as a template for amplification since this library 
has displayed good results in previous SELEX processes.[34-36] 
Similar yields of PCR amplification could be observed by 
agarose gel analysis when either the modified 5-CldUTP or the 
corresponding natural dTTP were used in PCR with the Taq 
polymerase. This further confirmed the potential of 5-CldUTP to 
serve as precursor for the construction of modified 
oligonucleotide libraries in lieu of dTTP. On the other hand, while 
the combination of 5-CldUTP and 7-deazadATP still produced 
significant PCR amplification, the yields were rather depleted 
compared to when the natural dNTPs were used 
(Supplementary data, S1).  
 
In vitro selection 
We applied the procedure described by Mayer et al. for the 
generation of ssDNA BACE1 aptamers using streptavidin–biotin 
chemistry to separate bound from unbound DNA species during 
the selection process.[37] In iterative cycles of selection, the 
library of ssDNA molecules with a random region flanked by 
defined primer binding sites was incubated with the biotinylated 
target protein (BACE1) immobilized on streptavidin-coated 
magnetic beads. (Scheme 1) Non-binding sequences were 
removed by washing steps while the bound species were eluted 
and amplified by PCR. The PCR products were captured on 
streptavidin magnetic beads via the biotinylated “antisense” 
strand. After washes of the beads, the unbiotinylated “sense” 
strands (i.e. the strands used for selection) were eluted from the 
beads by NaOH addition. This generated an enriched population 
of modified ssDNAs which represented the starting point for the 
next selection cycle.  
We carried out two selection experiments, one using 5-CldUTP 
as sole modification (SELEX A), while in the second approach 
both natural dTTP and dATP were replaced by 5-CldUTP and 7-
deazadATP, respectively (SELEX B). 
 
Scheme 1. SELEX strategy to identify anti-BACE 1 aptamers. A random 
ssDNA library is incubated with the intended target and separation of non-
binding sequences from bound sequences is achieved by using streptavidin 
(SV)-coated magnetic beads. The bound sequences are then eluted and 
amplified. Alkaline denaturation of the dsDNA leads to a new ssDNA enriched 
population ready for the next selection round. 
Prior to selection, BACE1 was biotinylated and coupled to 
streptavidin-coated magnetic particles which were then used 
directly in the in vitro selection experiment. We determined by 
Western Blot that a 5-fold Sulfo-NHS-LC-Biotin molar excess of 
biotinylation reagent was the best experimental condition to 
obtain high proportions of biotinylated vs. non-biotinylated 
protein (~1/3). Ideally, this would prevent a biotin ‘overload’ of 
BACE1 which could mask epitopes of interest during the 
selection with modified ssDNA. (Supplementary data, S2) The 
ratio of the total single stranded library to the target was 
evaluated to be approximatively 26:1. The quality of the PCR 
products was evaluated by agarose gel electrophoresis analysis 
(3%), and was considered successful when a properly sized 
XNA band was observed by UV monitoring. In this context, we 
observed that the quality of the XNA band improved during 
SELEX. Twelve iterations of SELEX were performed for both 
SELEX A and B. The stringency of the selection process was 
gradually increased (see Table 1). Variables affecting the 
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stringency included increasing the amount of wash steps and 
decreasing the amount of BACE 1 present on the beads.  
 
Table 1. Stringency conditions applied during the SELEX process.  
SELEX with 5-CldUTP instead of 
dTTP (SELEX A) 
SELEX with 5-CldUTP instead of 
dTTP  and 7-deazadATP instead of 
dATP (SELEX B) 
Round Washing 
cycles 
BACE1-
coated 
beads 
Round Washing 
cycles 
BACE1-
coated 
beads 
1 1 0.4 mg 1 1 0.4 mg 
2 2 0.4 mg 2 1 0.4 mg 
3 2 0.4 mg 3 2 0.4 mg 
4 4 0.33 mg 4 2 0.4 mg 
5 4 0.33 mg 5 3 0.4 mg 
6 4-5min; 
4-5 min 
0.33 mg 6 3 0.4 mg 
7 4-5min; 
4-5 min 
0.25 mg 7 4 0.4 mg 
8 4-5min; 
4-5 min 
0.25 mg 8 4 0.4 mg 
9 4-5min; 
4-5 min 
0.2 mg 9 5 0.4 mg 
10 4-5min; 
4-5 min 
0.2 mg 10 5 0.4 mg 
11 4-5min; 
4-5 min 
0.13 mg 11 6 0.06 mg 
12 4-5min; 
4-5 min 
0.13 mg 12 6 0.06 mg 
  
It is noteworthy to mention that all the selection experiments 
were carried out at the non-optimal pH of 7.4 and several 
attempts to perform SELEX at a pH of 4.5 (the optimum for 
BACE1 activity) failed due to absence of immobilization of the 
target on the magnetic beads. Indeed, estimation of BACE1 
biotinylation by Western blot and immobilization on streptavidin-
coated magnetic particles clearly revealed that BACE1 was not 
detected on the beads at such a low pH. The Streptavidin 
MagneSphere Paramagnetic Particles properties did not appear 
to be affected at this low pH since the yields of ssDNA 
purification from biotinylated PCR were comparable to those 
obtained at pH 7.4. In addition, the linker between BACE1 and 
the biotin is composed of stable amide bonds and the antibody 
used to detect BACE1 was able to identify the intended protein 
in the supernatant fraction at this pH. We rationalized that failure 
to carry out a SELEX with this protocol at a pH of 4.5 might be 
due to a lack of accessibility of the biotin to the streptavidin 
linked. This results from a subtle conformation modification of 
BACE1 at this acidic pH, since the pH-dependent flap dynamics 
that controls substrate accessibility did not seem to be drastic.[39] 
When the immobilization of the target was performed at pH 7.4 
but the pH was maintained at 4.5 during the SELEX process, no 
amplification was detected after a first round of selection. 
Another SELEX strategy without BACE1 biotinylation was then 
performed where the complexes of bound ssXNA to the target 
protein were separated from unbound reagents by filtration.[39] 
Unfortunately, no amplicon was obtained after the 11th round of 
selection despite several attempts.  
 
Cloning and sequencing analysis 
After 12 rounds of selection, PCR products were directly cloned 
and approximately one hundred positive clonal colonies were 
sequenced for both SELEX A and B to examine the diversity of 
molecules that remained in the pool. PCR amplicons from round 
7 (SELEX A) and 10 (SELEX B) were equally treated because of 
an unexpected loss of ssXNA during alkaline denaturation prior 
to the 8th round of the selection process. Examination of the 
sequences of the clones from SELEX A (with 5-ClU as modified 
nucleobase) revealed a major family of selected ssXNA 
represented by 8 sequences differing only by one to three 
nucleotides in the 49 nucleotide long randomized region. In 
addition, two other sequences were represented twice while all 
the remaining clones were unique sequences (Supplementary 
data, S3.1).[40] Interestingly, when we analysed the percentage 
of nucleotide frequency over all the sequences identified from 
SELEX A, we observed that 5-ClU was significantly the most 
represented nucleobase with 38.5% compared to only 14.8% for 
A, 15.2% for C and 31.5% for G. All the identified ssXNA 
sequences were synthesized by large-scale PCR and directly 
screened for activity on BACE1 through a MBP-C125APPsw 
assay. Surprisingly, of all the sequences only one stemming 
from the major family was active with a 30% inhibitory effect at 
0.25 µM. Twenty other clones were found to have an inhibitory 
effect comprised between 17 and 45% at higher oligonucleotide 
concentrations ranging from 0.26 to 0.86 µM. Another sequence 
was a strong activator and all the remaining sequences had no 
effect on BACE1. Unexpectedly, no particular common motif 
raised from the 21 ssXNA active clones through a Muscle 
multiple sequence alignment (Supplementary data, S3.2). 
Overall, all the identified sequences were different except for 
clones 12.6/23 (seq n°39) and 12.7/13 (seq n° 93) which were 
93.9 % identical. Examination of the cloned sequences 
stemming from SELEX B (with both 5-ClU and 7-deazaA as 
modified nucleobases) did not lead to the identification of clear 
families (Supplementary data, S3.3). However, almost half of the 
sequences (44 of 98) were primer dimer sequences 
(GCCTGTTGTGAGCCTCCTAACATGCTTATTCTTGTCTCCC) 
that most likely originate from a PCR amplification artefact rather 
than a true evolution of the sequence population during SELEX. 
Among the 56 remaining sequences, six were identical in pairs. 
The percentage of the nucleotides frequency over all these 
sequences was different from that of SELEX A since G was 
significantly the most represented nucleobase with nearly 36% 
compared to 26% for 5-ClU, and 19% for both 7-deazaA and C. 
Multiple local alignment of the sequence obtained from SELEX A 
and B did not reveal any identical sequence but three common 
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motifs (Supplementary data, S4.2). Following the sequence 
analysis, a few clones from SELEX B were synthesized by PCR 
and directly tested for activity using a FRET-based assay. The 
choice of the few selected clones was mainly based on the 
finding of the aforementioned common motif by the MEME 
program analysis tool (Supplementary data, S4).[41] 
The SELEX performed at pH 4.5 with 5-ClU as a modified 
nucleobase was also analyzed and PCR amplicons stemming 
from rounds 7 and 10 were cloned, sequenced and tested for 
activity. In this selection experiment, neither a clear sequence 
family nor a common motif could be identified within the 
sequences of the different clones which was expected due to the 
lack of sequence convergence. The percentage of the 
nucleotide frequency over all the sequences revealed that G 
was again significantly the most represented nucleobase with a 
value of 34.4% compared to 26.5% for 5-ClU, 20.5% and 18.6% 
respectively for A and C. Multiple local alignment of the 
sequences from SELEX A (ClU), SELEX B (5-ClU and 7-
deazaA) and SELEX at pH 4.5 (5-ClU) did not lead to the 
identification of any entire common sequence or any relevant 
common motif between the three SELEX processes.  
 
Activity and affinity studies 
 
ssXNA production 
ssXNA were produced in vitro by PCR using the intended 
recombinant plasmids as templates and carrying out strand 
displacement by alkaline denaturation and with the use of 
magnetic streptavidin beads as previously described. This 
method was validated by comparison with a PAGE purification of 
asymmetric PCR product. In the asymmetric PCR method, one 
of the primers (sl-REV-D1), consists of a repeating 5’-GC rich 
reverse sequence with the ability to form stem-loop structures 
and contains the 3’-complement sequence of the template. 
Therefore, the resulting PCR products exhibited two bands with 
different electrophoretic mobilities in denatured gel 
electrophoresis; the band with the highest mobility corresponds 
to the single stranded DNA template while the slower moving 
band corresponds to the extension product of sl-REV-D1 with a 
reverse repeating sequence of 30 nucleotides longer than the 
template.[42] ssXNA resulting from the method using magnetic 
separation or from the asymmetric PCR method were cloned 
and sequenced. Following purification by magnetic separation of 
the ssXNAs we observed one mutation in every 25 analyzed 
clones. The mutation rate was higher when the asymmetric PCR 
method was used (one mutation every 22 analyzed clones). The 
magnetic separation method was then selected for ssXNA 
production considering the faster protocol and the higher yield of 
ssXNA recovered for a similar quality of the sequences. Despite 
the fact that 5-CldUTP residues were described to pair with 
dATP but also with dGTP,[7] we didn’t observe significant 
misincorporation in place of 5-ClUTP residues (Supplementary 
data S7). This is consistent with a recent work where the base-
pairing abilities of oligonucleotides bearing one or three modified 
nucleosides were investigated showing the proper incorporation 
of modified dNTPs.[43] 
 
MBP-C125APPsw assay 
The effect of ssXNA on BACE1 was determined by application 
of an assay developed by Sinha et al.[44] Briefly, the exogenous 
recombinant maltose-binding protein MBP fused to APPsw (571-
695aa) was used as a substrate and its cleavage product 
released by the effect of BACE1 was detected by ELISA. This 
assay was used as a first screen to test the activity of the 
different ssXNA sequences resulting from SELEX A. From the 
one hundred and thirteen sequences that were tested, twenty 
displayed a moderate inhibition ranging from 17% to 45% in the 
tested concentration range (0.26-0.86 µM). These preliminary 
results were the starting point for more in-depth affinity studies 
and activity characterization. 
 
Binding assay 
We next investigated the binding of the twenty active ssXNAs to 
BACE1 by surface plasmon resonance studies (SPR). Among 
the twenty XNA sequences tested at 100 nM with the highest 
density of BACE1 (3136 RU), only ssXNA n°71 and the starting 
library were interacting significantly with BACE1. When BACE1 
was directly immobilized on the chip, a KD calculation was not 
possible because of very slow dissociation most likely due to 
avidity or more complex binding interaction than the 1:1 binding 
model. We then decided to perform kinetic studies with 
immobilized ssXNA in order to avoid avidity limitation. 
Biotinylated ssXNAs were immobilized on a streptavidin SA 
sensor chip with BACE1 as analyte. One representative SPR 
experiment with the responses for ssXNA n°71 over time, its 
unmodified counterpart 71T (with T nucleobase instead of 5-
ClU) and the initial library is shown in Figure 2 for BACE1 
concentrations from 0.156 to 10 µg/ml. 
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Figure 2. Sensorgrams were obtained from BACE1 injection over the 
immobilized biotinylated sequences A: 71, B: 71T and C: Library. The KD 
values for 71, 71T and the starting library are 12.0 ± 1.2 nM, 10.3 ± 3.7 nM 
and 31.0 ± 5.1 nM, respectively. 
 
An apparent equilibrium dissociation constant KD and kinetic rate 
constants (kon and koff) were calculated by fitting the 
experimental data using the 1:1 binding model (Supplementary 
data, S5). Strikingly, all three sequences displayed remarkably 
high affinity for BACE1 (12.0 ± 1.2 nM for clone n°71, 10.3 ± 3.7 
nM for clone n°71T and 31.0 ± 5.1 nM for the starting library). A 
slightly higher association rate constant (kon) and lower 
dissociation rate constant (koff) resulted in a 2.5-fold higher 
affinity of 71 and 71T compared to the library (Supplementary 
data, S5). The high affinity of the library for BACE1 could reflect 
a sequence bias of the starting pool with an overrepresentation 
of strong binders which are most likely non-specific. Lastly, all 
binding interactions were lost at physiological pH. Many SELEX 
endeavors making use of streptavidin magnetic beads in the 
selection protocol and especially cell-SELEX have to face 
considerable non-specific binding to these targets.[45] The 
addition of a counter selection against the matrix used for target 
immobilization should in theory reduce non-specific binding to 
the matrix. Fortunately, no binding to streptavidin nor spermidine 
was observed in our case (data not shown). 
 
Fluorescence resonance energy transfer (FRET) assay  
Dose-response studies were then conducted with an assay that 
did not require any specific antibodies and that could be adapted 
for small volumes. The assay is based on a method of 
fluorescence resonance energy transfer (FRET), in which the 
fluorescence signal is observed after a smaller peptidic 
substrate is cleaved by BACE1. First, a decrease in BACE1 
activity of 70,4 ± 5,2% (n=3 independent experiments) was 
observed when the assay buffer was supplemented with NaCl, 
KCl and MgCl2. This is possibly due to an alteration of the 
secondary structure of the protein. ssXNA 71, a randomly 
generated sequence variant of 71, and 71T, were tested in this 
assay and compared to the previously identified DNA aptamer 
Apt_A1 against BACE1.[31] In addition, sequences 39 and 93, 
extracted from the major class of sequences isolated after 12 
rounds in SELEX A, the chemically synthesized analogue of 93 
depleted of the primer regions and the sequence 118 selected 
during SELEX B with two modified nucleobases were also 
assessed. (Table 2) 
 
Table 2. Sequences of selected ssXNA. X= 5-ClU and P= 7-deazaadenine, 
motif 1 is highlighted in red, motif 2 in cyan, motif 3 in green. 
 Sequences 
71 gcctgttgtgagcctcctaacGGCGXAGGGXXXGXXGXCXCXAXXXCXXXG
XAXXGXGXXGXGXXCGCXcatgcttattcttgtctccc 
71T gcctgttgtgagcctcctaacGGCGTAGGGTTTGTTGTCTCTATTTCTTTG
TATTGTGTTGTGTTCGCTcatgcttattcttgtctccc 
Ran
dom 
71 
gcctgttgtgagcctcctaacXCXXGXGCXCGXXGXCCAXGXGGXXGXGGA
XXXGXXGCGXGAXXXXXXcatgcttattcttgtctccc 
39 gcctgttgtgagcctcctaacGCACCGGXCGCAGGXXXAGCAAGGXCACAA
GCXGGCAXCAAGGXXGCXXcatgcttattcttgtctccc 
93 gcctgttgtgagcctcctaacGCACCGGXCGCAGGXXXAGCAAGGXXACAA
GCXGGCAXXAAGGXXGCXCcatgcttattcttgtctccc 
93 
TL 
GCACCGGXCGCAGGXXXAGCAAGGXXACAAGCXGGCAXXAAGGXXGCXC 
118 gcctgttgtgagcctcctaacGCPCXCXGGXCGCPXGXGGPGXPXCCGPXX
XGGXXGPGXXCGXXXGCXCcatgcttattcttgtctccc 
Apt_
A1 
gcaatggtacggtacttccGTCATCAGCTTGTGATGTGGATGCGAACTGca
aaagtgcacgctactttgctaa 
The letters in lower case stand for the primer sequences used for 
amplification. Random 71 was generated using the tool: http://users-
birc.au.dk/biopv/php/fabox/random_sequence_generator.php 
 
In this assay, all the selected ssXNA sequences modulated 
BACE1 in the same unusual manner i.e. a dose-dependent 
effect was first observed for the lowest concentrations of 
oligonucleotides tested followed by an increase in BACE1 
activity at the highest concentrations. (Figure 3 A1, B, C and D. 
The loss of inhibition for high concentrations of ssDNA or ssXNA 
could be due to a loss of accessible oligonucleotides caused by 
an aggregation phenomenon or due to an activating effect on 
BACE1 at high concentrations. 
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Figure 3. Modulation of BACE1 activity by ssXNA or ssDNA in a FRET assay. 
For clarity concern, the graphs were split into A, B, C and D panels with 
Apt_A1 as a reference. A2 corresponds to A1 graph without the plot of the 
highest concentration values for 71 to allow IC50 determination. 
The results suggested that the XNA sequences had an 
activating effect at higher concentrations which is not observed 
with the reference aptamer Apt_A1. However, this trend did not 
seem to be associated to the presence of chemical modifications 
nor to the in vitro production method since sequences 71T 
(synthesized by the in vitro production method) and 93 TL 
(chemically synthesized) also exhibited the same profile. 
Moreover, at a concentration of 10 µM, ssXNA 39 produced a 
slight activating effect instead of a loss of inhibition. At higher 
concentrations, the selected ssXNA or ssDNA could bind with a 
lower affinity to an allosteric site. The IC50 values (95% CI) for 
the tested sequences were estimated without taking into account 
the data for high concentration of modulator (1.1; 3.3 and 10 µM 
Figure 3 A2). We found an IC50 value for Apt_A1 of 138.7 nM 
that was very close to the value initially described (i.e. 139.81 
nM) and slightly lower IC50 values (46 to 95 nM) for all the other 
sequences (Table 3).  
 
Table 3. Activities of representative ssXNA BACE1 inhibitors (and 
related analogues) isolated by directed evolution.  
aptamer IC50   KD 
71 130.8 nM (95% CI: 75.6 to 226.2 nM) 12.0 ± 1.2 nM 
71T 61.9 nM (95% CI: 43.7 to 87.6 nM) 10.3 ± 3.7 nM 
Random 71 52.5 nM (95% CI: 36.8 to 75.0 nM)  
39 46.5 nM (95% CI: 37.2 to 58.2 nM)  
93 52.9 nM (95% CI: 39.1 to 71.5 nM)  
93 TL 94.6 nM (95% CI: 61.9 to 144.6 nM)  
118 85.4 nM (95% CI: 64.1 to 113.8 nM)  
Apt_A1 138.7 nM (95% CI: 90.2 to 213.1 nM)  
 
 
From this biochemical analysis, several different hypothetical 
binding motifs could be inferred for the binding effect of the 
sequences on BACE1. Indeed, the sequence motif R-RRGRG-
RCG (R = X or T, motif 1, Table 2) was common to sequences 
71, 71T and random 71 (see MEME results in Supplementary 
data S4.3). On the other hand, sequences 39 and 93 could 
contain two motifs, one shared with 93TL and another one with 
118 that might explain their slightly lower IC50 values. The motif 
shared between 118, 39 and 93 might expand from the 5’-primer 
to the core region (motif 3 in green Table 2). This hypothesis 
could also explain why 93TL exhibited a two times lower activity 
compared to 93. However, no common motif with Apt_A1 could 
be clearly identified except a very short CTTGTG motif that 
could be a start for further truncation investigation (truncated 
motif 1 in red Table 2). Finally, the variability of the sequences 
generated from the different SELEX processes and the results of 
the activity assay suggest that BACE1 displays multiple binding 
sites for aptameric nucleic acids.  
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Conclusions 
To summarize, we have included base-modified triphosphate 
analogs in the SELEX processes to raise aptamers against beta-
secretase 1. The resulting aptamers displayed a remarkable 
affinity for the target (~10 nM Kd values) with IC50 values in the 
low nM range. In addition, while the selection of ssXNAs was 
conducted at pH 7.4, the aptamers conserve their activity and 
high binding affinities at pH 4.5 which is optimal for the BACE1-
mediated peptide cleavage activity.[46,47] This feature may be 
related to allosteric exosite binding rather than a competitive 
inhibitory effect with the natural substrate; this hypothesis is 
consolidated by results from BACE1 conformational switch 
studies based on crystal structure resolution and continuous 
constant-pH molecular dynamics simulations.[46,38] The ssXNA 
aptamer identified as sequence 71 not only tightly binds to 
BACE1 (Kd = 12 nM), but also inhibits its protease activity in vitro 
in the same range as a previously described unmodified 
aptamer.[31] Surprisingly, other selected candidates like n°39 and 
93 were good modulators of BACE1 activity without any 
detectable binding to BACE1, revealing that strong binding might 
not be the only crucial parameter determining the capacity of an 
aptamer to modulate the activity of an enzyme. In contrast, the 
starting library displayed a significant affinity to BACE1, most 
likely due to a sequence bias caused by a statistic 
overrepresentation of strong binders in the starting pool. The 
newly identified ssXNA aptamer has a similar affinity compared 
to the same unmodified oligonucleotide despite differences in 
association and dissociation rate constants. However, all the 
selected sequences had new features in terms of activity with an 
unusual behaviour of modulator that was concentration-
dependent. Different aptamers with allosteric modulatory activity 
have already been identified but each aptamer was selective for 
one conformational state of the target.[48] The vast majority of 
aptamers described in the literature have an inhibitory effect on 
their enzymatic target. There are only a few examples of 
aptamers with an agonist effect on receptors and only one 
example to the best of our knowledge with an activating effect 
on thrombin.[49] Even if agonist-antagonist compounds are well 
known in a drug-receptor interaction context, we are not aware 
of any aptamer with an inhibitory effect at low concentration and 
an activating effect at high concentration on its target. Here, it 
appeared that one ssXNA and the same aptameric sequence 
could modulate BACE1 activity depending on its concentration. 
This study paves the road towards more aptamer 
xenodiversification and the identification of potent inhibitors, 
especially for the treatment of neurodegenerative diseases. 
Aptamers have not frequently been used as agents in this field 
so far, mainly because of the difficult nature of the targets as 
illustrated by BACE1. 
While C5-modified nucleotides have been used for some time in 
SELEX procedure leading especially to SOMAmers[50] or to 
alkyne-modified aptamers identification,[51,52] we selected a fully 
substituted 5-CldU aptamer that can potentially be produced 
within a bacterium with the use of a specialized polymerase. 
One unnatural base pair was integrated and replicated for the 
first time on a plasmid in E. coli by Romesberg and colleagues in 
2014.[15] If such a base pair could be stably maintained, it could 
allow an expansion of the genetic code with numerous 
applications. ChloroU substitution has been shown to be stably 
inherited in the chromosome of E. coli as an information 
support.[2] The next step would be to introduce non coding but 
functional XNA as a selected aptamer in such a living system 
which function could be controlled exogenously and over time. 
Experimental Section 
General 
Synthesis of modified precursors: 5-chloro-2’-deoxyuridine and 7-deaza-
2’-deoxyadenosine were converted to their 5′-triphosphates in a one-pot 
reaction by the Ludwig method.[53,54]                                                        
DNA sequences: DNA oligonucleotides were purchased from Eurofins 
(France) and purified by HPLC. The sequences are the following (shown 
5’ to 3’): FWD-D1 GCCTGTTGTGAGCCTCCTAAC; Bio-REV-D1 (5’-
BITEG modified) GGGAGACAAGAATAAGCATG; sl-REV-D1 (in bold the 
5’-GC rich reverse repeat sequence with the ability to form stem-loop 
structure) 
CCGCGGGTGGGACTTCCTAGTCCCACCCGCGGGAGACAAGAATAA
GCATG; Bio-FWD-D1 (5’-BITEG modified) 
GCCTGTTGTGAGCCTCCTAAC; T3 AATTAACCCTCACTAAAGGG; T7 
TATACGACTCACTATAGGG. The single strand oligonucleotide n°93 TL 
(5’- GCA CCG GXC GCA GGX XXA GCA AGG XXA CAA GCX GGC 
AXX AAG GXX GCXC-3’) was chemically synthesized by TriLink 
company.                                                                                              
Human BACE1 ectodomain containing the catalytic domain of the 
protease (residues 46-460) was kindly provided by Bart de Strooper after 
production in HEK293T cells (VIB Protein Service Facility, Department of 
Molecular Biomedical Research Technologiepark 927, B9052 Ghent, 
Belgium).                                                                                              
Starting materials, reactants and solvents were obtained from Sigma-
Aldrich at a molecular biology grade when available. 
Amplification studies with a modified triphosphate precursor: We 
determined for the D1 DNA library with a random region of 49 bases (5’-
GCC TGT TGT TGT CCT CCT AAC (N49) CAT GCT TAT TCT TGT CTC 
CC-3’, Metabion, Germany) an extension efficiency of 52%, a complexity 
of the pool of 8.84x1015 and an average amplification efficiency of the 
PCR product of 1.81. D1 library was amplified by using the following 
optimized conditions: 50 nM template, 3.5 mM MgCl2, 200 µM dNTP 
(modified or natural), 1 µM forward FWD-D1 and reverse REV-D1-Bio 
primers, 0.5 mg/mL BSA, 0.025 U/µL TAQ polymerase (TAQ DNA 
polymerase Thermus aquaticus YT-1, New England Biolabs), 95°C 1 min, 
54°C 1 min, 72°C 1.5 min, 6 cycles. These optimal reaction conditions 
enabled the setting of the large scale PCR that resulted in the generation 
of 10 copies of the library with a ca. 1014 complexity. Incorporation of 5-
CldUTP was also obtained with similar yield by using the AmpiTAQ Gold 
DNA polymerase (Applied Biosystems) using the same conditions. 
In vitro selection: The SELEX methodology outlined below was adapted 
from the work of Mayer et al.[37] Strand displacement assays: The 
library used for the selection was obtained after generation of single-
stranded XNA. Reverse primer was biotinylated at the 5’ end to enable 
the removal of the reverse complement by using streptavidin-coated 
magnetic beads.[35] After immobilization of a 100 µL aliquot of the PCR-
built library on magnetic beads (0.25 mg, Promega) in a 300 µL final 
binding volume (5 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 1 M NaCl) and 
elution of the non-biotinylated strand by addition of 50 µL 0.15 M NaOH 
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followed by HCl neutralization (25 µL of 0.3 N HCl), approximatively 40 
pmol of ssXNA were recovered per aliquot for SELEX A and 15 pmol for 
SELEX B. Quantitation of the oligonucleotides was done by recording the 
UV absorption at 260 nm by using the base composition method for εM 
calculation (εM = 9500 M-1.cm-1 for 5-CldUTP and 12 000 M-1.cm-1 for 7-
deazadATP) and assuming an identical distribution of the four 
nucleotides in the library random region. In order to improve the ssXNA 
production yield and to avoid issues associated to the streptavidin coated 
beads,[45] an alternative method has been tested by using a 5’-
phosphorylated reverse primer instead of the biotinylated one for PCR 
amplification followed by exonuclease λ digestion (New England Biolabs, 
France).[55] Despite several benefits associated to this method including a 
better yield purification or a less expensive process, we chose to carry on 
with the streptavidin magnetic beads because of significant drawbacks 
like remaining dsXNA in the reaction,[56] longer time in duration and 
reproducibility problems of quantification by UV/Vis spectroscopy. 
BACE1 immobilization procedure: Firstly, 6.66 nmol BACE1 
ectodomain (residues 46-460 containing the catalytic domain of the 
protease) were incubated on ice with 33.3 nmol EZ-Link Sulfo-NHS-LC-
Biotin (Thermo Scientific) reagent (in a total volume of 400 µL for 30 
minutes and further 15 minutes at room temperature. Unbound sulfo-
NHS-LC-Biotin reagent was removed from the mixture by gel filtration by 
using P6 spin-columns (BioRad). We obtained a 1:3 ratio mixture of 
biotinylated and unbiotinylated BACE1 after Western blot determination 
by using streptavidin beads immobilization experiment (Supplementary 
data, S2). BACE1 biotinylation mixture (0.48 nmol, 50 µL) was added to 
2.5 mg of streptavidin paramagnetic particles (MagneSphere, Promega) 
in 1 mL selection buffer (137 mM NaCl, 2.7 mM KCl, 6.5 mM Na2HPO4, 
1.8 mM NaH2PO4, 1.5 mM MgCl2 and 0.1% (w/v) BSA, pH 7.4) and 
incubated for 30 minutes at room temperature under constant agitation. 
The supernatant was then removed and the beads were washed and 
resuspended in 1 mL selection buffer. Uncoated beads were generated 
by using the same protocol, but without a protein ligand. These beads 
were used in the counter-selection steps outlined below in order to 
remove oligonucleotides that may bind non-specifically to the 
unfunctionalized regions of the beads. In vitro enrichment of ssXNA: 
The SELEX procedure began with a preincubation of 500 pmol ssXNA 
for SELEX A and 215 pool for SELEX B with 0.4 mg of non-loaded 
streptavidin-coated magnetic beads for the counter selection step in a 
total volume of 400 µL selection buffer (137 mM NaCl, 2.7 mM KCl, 6.5 
mM Na2HPO4, 1.8 mM NaH2PO4, 1.47 mM MgCl2 and 0.1% (w/v) bovine 
serum albumin (BSA), pH 7.4) at room temperature. Following incubation, 
the beads were partitioned by using a magnet and the supernatant was 
immediately added to 0.4 mg BACE1-coated beads in a total volume of 
400 µL selection buffer for 30 minutes at room temperature. After 
washing with selection buffer, BACE1-bound sequences were eluted by 
incubation in 250 µL water at 95°C for 3 min, concentrated in vacuo and 
resuspended in 30 µL H2O and reamplified with suitable primers. The 
beads were discarded after each round of selection. The first PCR 
proceeded according to the previously determined conditions in a final 
volume of 100 µL. The second PCR proceeded in a 2 mL final (SELEX A) 
or 1 ml (SELEX B) volume by the first PCR as the template. After alkaline 
denaturation of the double-stranded PCR products, filtration on Omega 
membrane (Nanosep centrifugal devices, Pall Life Sciences), 10% of 
desalted “sense” strands were kept aside as safeguard and the rest was 
introduced to the subsequent rounds of SELEX. Twelve iterations of 
SELEX were performed.  In vitro selection by using nitrocellulose 
membrane at pH 4.5: SELEX was performed as described by Hall et al. 
by using nitrocellulose membrane to select aptamers against BACE1 at 
pH 4.5.[37] In every round, prior to selection, ssXNA were thermally 
equilibrated and refolded in selection buffer by heating to 75°C for 3 min 
and then slowly cooling to 37°C for at least 10 minutes. To minimize 
nonspecific binding with the nitrocellulose membrane, the ssXNA pool 
were pre-adsorbed to a 0.45 µm nitrocellulose HAWP nitrocellulose disk 
filter (Analytical Biotechnology, Birkhauser) for 30 min prior to every 
round of selection in order to remove filter-binding species. In the first 
selection cycle, the random ssXNA pool (500 pool in 100 µL selection 
buffer at pH 4.5) and BACE1 (25 pool in 100 µL selection buffer at pH 
4.5) were incubated in a rotating wheel for 30 min at room temperature. 
The stringency conditions for the following rounds are described in 
Supplementary data, S6. The BACE1 bound ssXNA were eluted from the 
filter with 200 µL TE Buffer (7 M urea, 25  mM EDTA pH=8) at 95°C for 
5 min, followed by ethanol precipitation. 
Cloning and sequencing analysis: PCR products with unbiotinylated 
primers FW-D1 and REV-D1 were directly inserted into the TOPO® TA 
cloning vector (Life Technologies) according to manufacturer instructions. 
After transforming the loaded vector into competent β 2033 E. coli K12 
strain,[57] the bacteria were plated onto ampicillin selective Petri dishes 
(10, 20, 40 and 200 µL transformation) at 37°C with an overnight 
incubation. One hundred and twelve positive clonal colonies for SELEX A, 
one hundred and eight for SELEX B were randomly picked and grown in 
liquid LB Amp (100 µg/ml) media and plasmids were purified by using a 
QIAprep Spin Miniprep Kit according to manufacturer instructions 
(QIAGEN). An aliquot of all liquid cultures was stored at -80°C in 15% 
glycerol final concentration for further production and analysis. The 
sequencing using the Sanger method was carried on at the sequencing 
department of Genoscope (Evry, France) by using the T7 and T3 
sequencing primers that were incorporated into the TOPO TA vector. The 
sequences were assessed for quality i.e. proper length and sequence, 
trimmed to removed primer sequences and then aligned with « Geneious 
version 6.1.6 (http://www.geneious.com,[40]) and Muscle alignment 
tool.[58] For SELEX B, a few sequences were selected to be tested for 
activity based on MEME results analysis (Supplementary data, S4.1).[59] 
ssXNA production: dsXNA were first obtained after PCR amplification 
by a low error rate DNA polymerase (TaKaRa Ex Taq, Ozyme) by 
applying the following conditions: 2 mM MgCl2 in the proper 1x buffer, 0.2 
mM standard dNTP, 0.14 mM modified dNTP, 1 µM primers FW-D1 and 
REV-D1-Bio, 0.025U/µL TaKaRa Ex Taq, 95°C for 30 sec, 54°C for 30 
sec, 72°C for 1 min, 30 cycles seeded with 4.3 ng/µL of each 
corresponding purified plasmid as template in a 3.8 mL total volume. 
Alkaline denaturation of the PCR product resulted in ~1500 pmol ssXNA 
with the use of streptavidin magnetic beads as previously described.  
The quality of the ssXNA production process was compared to another 
method with unequal length strand PCR and PAGE purification.[42] Two 
500 µL-PCR were set in parallel. Using the primers FWD-D1 and sl-REV-
D1, the unequal length of ssDNA molecules were produced as follows: 2 
mM MgCl2 in the proper 1x buffer, 0.2 mM standard dNTP, 1 µM primers, 
0.025U/µL TaKaRa Ex Taq seeded with 2150 ng of clone 7.8/60 (n°71) 
purified plasmid from SELEX A as template. PCR products of unequal 
length strand were analyzed by electrophoresis in a 6% polyacrylamide 7 
M urea gel and the lower band of interest was purified by electroelution in 
0.5x TBE buffer and ethanol precipitation. The same PCR conditions 
were used for the second 500 µL test PCR except the primers FWD-D1 
and REV-D1-Bio and the ssDNA were then recovered as previously 
described after binding and denaturation on magnetic streptavidin coated 
beads. One method resulted in to 200 pmol of ssDNA and the other 
method to less than 100 pmol, starting from a 500 μL-PCR in both cases. 
The resulting ssDNA from both conditions were PCR amplified with the 
corresponding unbiotinylated primers (50 µL final volume, 35 nM as 
template and 5 cycles), cloned and sequenced (Supplementary data, S7).  
The asymmetric PCR procedure was used to produce 5’-biotinylated 
ssXNA for binding analysis. Using the primers Bio-FWD-D1 and sl-REV-
D1, the unequal length of ssDNA molecules were produced as follows: 2 
mM MgCl2 in the proper 1x buffer, 0.2 mM standard dNTP, 0.14 mM 
modified dNTP, 1 µM primers, 0.025U/µL TaKaRa Ex Taq seeded with 
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4.3 ng/µL of the selected plasmid or 70 nM for the library in a final 
volume of 1 mL. The mixture was thermally cycled 30 times through 95°C 
for 1min, 37°C for 30s and 58°C for 40s, and followed by 5 min extension 
at 58°C. PCR products of unequal length strand were analyzed by 
electrophoresis in a 6% polyacrylamide 7 M urea gel and the lower band 
of interest was purified by electroelution in 0.5x TBE buffer and ethanol 
precipitation.  
BACE1 MBP-C125APPsw assay:[60] Human BACE1 (1-460): Fc was 
diluted in reaction buffer (48 mM ammonium acetate pH 4.6, 1 mg/ml 
BSA and 0.7% Triton X-100) till a final concentration of 10 nM. Substrate 
fusion protein of maltose binding protein (MBP) and 125 amino acids of 
the carboxyl terminus of human APP containing Swedish double 
mutation was diluted till 50 nM in reaction buffer. 30 µL test ssXNA was 
incubated with 50 µL substrate and 20 µL enzyme at 25°C for 3 hours. At 
the end of the incubation, the reaction mixture was 5-fold diluted in stop 
buffer (100 mM Tris pH 8.0, 6 mg/mL BSA and 10 mM Triton X-100). 50 
µL of the diluted reaction mixture was then loaded on an ELISA plate pre-
coated with anti-MBP antibody. The cleavage product MBP-C26sw was 
detected by a neo-epitope antibody against the BACE1 cleavage site. 
The activity of BACE1 was proportionally related to the amount of 
cleavage product.  
Surface plasmon resonance measurements: Surface plasmon 
resonance (SPR) measurements were carried out on a Biacore T200 
(GE Healthcare, Uppsala, Sweden). In a first set of experiments BACE1 
was immobilized on a CM4 chip using standard amine coupling chemistry. 
To determine the binding kinetics and affinities, biotinylated ssXNA were 
captured on a commercial streptavidin SA sensor chip (88 RU for the 
library, 69 RU for 71 and 84 RU for 71 T). A reference flow cell was used 
as a control for non-specific binding and refractive index changes. Buffer 
blanks were used for double referencing. All interactions were performed 
in 48 mM ammonium acetate pH 4.6, 0.7% Triton X-100, 137 mM NaCl, 
2.7 mM KCl and 1.5 mM MgCl2. The regeneration conditions applied were 
1 M NaCl and 10 mM NaOH. The estimated affinities and rate constant 
values resulted from five independent experiments and were determined 
using the Biacore T200 Evaluation Software 2.0.  
Fluorescence resonance energy transfer (FRET) assay: This assay 
was adapted from β-Secretase 1 (BACE1) Activity Detection Kit protocol 
(Sigma-Aldrich, St. Louis, MO). Briefly, all the components were 
prepared and the assay buffer at pH 4.6 supplemented with NaCl, KCl 
and MgCl2 at final concentrations of 137 mM, 2.7 mM and 1.47 mM, 
respectively. The BACE1 substrates were diluted down to a 
concentration of 30 µM in this salty assay buffer. BACE1 enzyme was 
prepared in the same buffer at a concentration of 0.045 units/µL. Stock 
solutions of test samples were prepared in the appropriate buffer (1650 
pmol in 55 µL of salty assay buffer) and then serially diluted to give the 
desired working concentrations ranging from 30 µM to 0.014 µM. 10 µL 
of BACE1 enzyme, substrate, standard, test samples and salty buffer 
were then added in turn to the wells for a total volume of 30 µL, with the 
BACE1 enzyme being added last. 384-wells plates (Corning™ 384 Well 
Flat Clear Bottom Polystyrene NBS™ Microplates) were then covered 
with an adhesive aluminum foil and incubated at 37°C for 2 hours. 
Fluorescence units (FU) were recorded on a fluorometer CLARIOstar 
(BMG LABTECH GmbH, Ortenberg, Germany) set with excitation at 320 
nm and emission at 405 nm.  The percentage of BACE1 activity was 
calculated by using the following equation: y = FUssXNA/FUo×100, 
where FUssXNA and FUo represent the fluorescence units in the 
presence and absence of ssXNA after subtraction of the blank (substrate 
in the salty assay buffer). Dose-response curves were created by 
graphing the percentage of BACE1 activity versus the logarithm of the 
inhibitor concentration. All experiments were performed in triplicate. 
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